title: Detrimental vascular effects of lysophosphatidylcholine is limited by other phospholipid components of low-density lipoprotein.
abstract: Current consensus suggests that lysophosphatidylcholine is the major detrimental factor in oxidized low-density lipoprotein that may contribute to the alterations of vasomotor responses associated with atherosclerosis. This study investigated the influences of lysophosphatidylcholine and major lipid components in oxidized low-density lipoprotein on vascular relaxation. We also determine if there was any interaction between these phospholipid components on relaxation. Porcine coronary artery rings were incubated with lysophosphatidylcholine, phosphatidylcholine or sphingomyelin. After contraction by the thromboxane A2 mimetic U46619, rings were relaxed with bradykinin and calcium ionophore A23187. Lysophosphatidylcholine with a higher proportion of stearoyl-lysophosphatidylcholine to palmitoyl-lysophosphatidylcholine ratio caused greater reduction of relaxational responses. While phosphatidylcholine and sphingomyelin had no effect on vascular relaxation, they reduced the ability of lysophosphatidylcholine to impair vascular relaxation. Our results thus suggested that the effectiveness of oxidized low-density lipoprotein at inhibiting vasodilatory responses may be determined by the relative proportion of different types of lysophosphatidylcholine as well as the amount of other phospholipid components: phosphatidylcholine and sphingomyelin.
authors.affiliation: Department of Pharmacology, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR.
authors.forename: Susan W S
authors.initials: SW
authors.lastname: Leung
authors.forename: Min
authors.initials: M
authors.lastname: Huang
authors.forename: Ricky Y K
authors.initials: RY
authors.lastname: Man
mesh_terms: D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D000818:Animals; D001161:Arteriosclerosis; D001920:Bradykinin / Q000378:metabolism; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002417:Cattle; D003331:Coronary Vessels / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000378:metabolism; D007476:Ionophores / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008099:Liver / Q000378:metabolism; D008244:Lysophosphatidylcholines / Q000737:chemistry / Q000494:pharmacology*; D010100:Oxygen / Q000378:metabolism; D010713:Phosphatidylcholines / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism*; D013109:Sphingomyelins / Q000378:metabolism; D013552:Swine; D013928:Thromboxane A2 / Q000378:metabolism; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D007476:Ionophores; D008077:Lipoproteins, LDL; D008244:Lysophosphatidylcholines; D010713:Phosphatidylcholines; D010743:Phospholipids; D013109:Sphingomyelins; D014662:Vasoconstrictor Agents; D000001:Calcimycin; D013928:Thromboxane A2; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D010100:Oxygen; D001920:Bradykinin; D002118:Calcium